Endo News Roundup: Promising Diabetes Therapies

June 8, 2016
Mark L. Fuerst

Three new studies highlight promising diabetes drug treatments to help patients who struggle with severe hyperglycemia.

New drugs show promise in treating type 2 diabetes mellitus (T2DM) patients with severe hyperglycemia, and may also lower cardiovascular disease (CVD) risks and reduce glucose variability. Here are the highlights from three new studies: a combination of saxagliptin and metformin is effective in treating severe hyperglycemia in patients with new-onset T2DM. T2DM patients treated with dipeptidyl peptidase-4 (DPP-4) inhibitors may have lower risks for CVD as compared to those for non-DPP-4 inhibitor users, except for those taking metformin. Insulin-dependent T2DM patients show reduced glucose variability when treated with a glucagon-like peptide 1 (GLP-1) agonist.